-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy

MT Newswires·09/09/2026 02:02:42
Listen to the news
02:02 AM EDT, 09/09/2026 (MT Newswires) -- Evotec (EVT.F) said Wednesday it launched a phase 1 clinical trial of JST-018, a cocktail of monoclonal antibodies being evaluated as prophylactic therapy against orthopoxviruses. The German life science company's biologics contract development and manufacturing organization subsidiary, Just - Evotec Biologics, developed the antibodies under the US Department of War's Accelerated Antibodies Program, marking its second project with the department. Just - Evotec Biologics' two contracts with the department have a combined value of up to $123.9 million.